NURIX THERAPEUTICS, INC. Payments to Acquire Investments
NURIX THERAPEUTICS, INC. (NRIX) reported Payments to Acquire Investments of $239.37 million for the 12-month period ending 2022-11-30, per its 10-K filed 2023-02-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2023-02-09
- NURIX THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2022-05-31 was $64.79M, a 52.19% decline year-over-year.
- NURIX THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2022-02-28 was $15.24M, a 68.07% decline year-over-year.
- NURIX THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2021-11-30 was $90.68M, a 32.40% decline year-over-year.
- NURIX THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2021-08-31 was $74.58M, a 33.07% decline year-over-year.
- NURIX THERAPEUTICS, INC. payments to acquire investments for fiscal 2022 was $239.37M, a 31.31% decline from fiscal 2021.
- NURIX THERAPEUTICS, INC. payments to acquire investments for fiscal 2021 was $348.50M, a 26.62% increase from fiscal 2020.
- NURIX THERAPEUTICS, INC. payments to acquire investments for fiscal 2020 was $275.22M, a 2843.26% increase from fiscal 2019.
- NURIX THERAPEUTICS, INC. payments to acquire investments for fiscal 2019 was $9.35M.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2022-11-30 | $239.37M 10-K · filed 2023-02-09 | |||
| 2022-05-31 | $64.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | $80.03M 10-Q · filed 2022-07-07 | $170.72M derived: sum of 3 quarters · filed 2023-02-09 | $245.29M derived: sum of 4 quarters · filed 2023-02-09 |
| 2022-02-28 | $15.24M 10-Q · filed 2022-04-08 | $105.93M derived: sum of 2 quarters · filed 2023-02-09 | $180.50M derived: sum of 3 quarters · filed 2023-02-09 | $316.00M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-11-30 | $90.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $165.26M derived: sum of 2 quarters · filed 2023-02-09 | $300.75M derived: sum of 3 quarters · filed 2023-02-09 | $348.50M 10-K · filed 2023-02-09 |
| 2021-08-31 | $74.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | $210.07M derived: sum of 2 quarters · filed 2022-07-07 | $257.81M 10-Q · filed 2021-10-14 | $391.97M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-05-31 | $135.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | $183.24M 10-Q · filed 2022-07-07 | $317.39M derived: sum of 3 quarters · filed 2022-07-07 | $428.82M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | $47.74M 10-Q · filed 2022-04-08 | $181.90M derived: sum of 2 quarters · filed 2022-04-08 | $293.33M derived: sum of 3 quarters · filed 2022-04-08 | $303.91M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | $134.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $245.58M derived: sum of 2 quarters · filed 2022-01-28 | $256.16M derived: sum of 3 quarters · filed 2022-01-28 | $275.22M 10-K · filed 2022-01-28 |
| 2020-08-31 | $111.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | $122.01M derived: sum of 2 quarters · filed 2021-10-14 | $141.07M 10-Q · filed 2021-10-14 | $144.48M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | $10.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-13 | $29.64M 10-Q · filed 2021-07-13 | $33.05M derived: sum of 3 quarters · filed 2022-01-28 | |
| 2020-02-29 | $19.06M 10-Q · filed 2021-04-13 | $22.47M derived: sum of 2 quarters · filed 2022-01-28 | ||
| 2019-11-30 | $3.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $9.35M 10-K · filed 2022-01-28 | ||
| 2019-08-31 | $5.94M 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |